Blood Cancer Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

FDA Approves Tregzi: A New Way to Reduce Complications After Blood Cancer Transplants

FDA Clears AbbVie’s Decnupaz for Ultra-Rare Blood Cancer BPDCN

World Blood Cancer Day 2026: New FDA Approvals and Phase III Readouts

Redefining Hematologic Malignancy Drug Development: How Molecular Reclassification, MRD, & AI is Reshaping Precision Hematology

Roche’s Subcutaneous Lunsumio Velo Receives FDA Approval for Follicular Lymphoma

January 21, 2026

Blenrep Combination Wins FDA Nod in Relapsed or Refractory Multiple Myeloma

October 24, 2025

World Blood Cancer Day 2025: New Strides in Treating Leukemia, Lymphoma and Rare Blood Malignancies

Acute Leukemia Drug Revuforj Wins FDA Approval, Second Approval for Syndax this Year

November 28, 2024

Clinical Trial News

Tamibarotene Fails in Phase III Trial for a Subset of Higher-Risk MDS

November 15, 2024

Autolus Wins FDA Approval for B-ALL CAR T-Cell Therapy Aucatzyl, May Have Edge Over Competitors

November 12, 2024

Gene Therapy Skysona Linked to 7 Cases of Blood Cancer

October 15, 2024

After Three Decades in the Making, Geron’s Telomerase Inhibitor Rytelo Gets FDA Nod for Lower-Risk MDS

J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma

FDA Advisory Committee Backs Carvykti and Abecma for Earlier Myeloma Treatment

FDA Raises Concerns Over Early Trial Deaths for CAR T-Cell Therapies Carvykti and Abecma

Ojjaara Is GSK’s New Treatment for Anemic Myelofibrosis Patients

September 25, 2023

Next Page »